— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.
— During the fourth quarter, the company recorded impairment charges of $155 million.
— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.
— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.
— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.
— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.
— AMAG stock had retreated 24% in the past three months and 45% from this time last year.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
